TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29071914

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zigong (EX-CA 1) and Tianshu (ST 25) combined with manual acupuncture at Sanyinjiao (SP 6) and Guanyuan (CV 4) for 8 weeks (30 min, 10 Hz/50 Hz, 3 times a week).
Number of subjects: 58

Group type: COMPARATOR
Intervention: Medication group receiving estradiol valerate (1 mg/day for 3 weeks, followed by a week of rest, then 1 mg/day and medroxyprogesterone 17-acetate (8 mg/day) for 10 days).
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Acupuncture group (EA and manual acupuncture).
Number of subjects: 58
Study: 24103107

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 170

Group type: COMPARATOR
Intervention: not applicable
Number of subjects: 170
Study: 22233103

Group type: EXPERIMENTAL
Intervention: Mental simulation intervention
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Combined mental simulation and implementation intention intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: No mental simulation
Number of subjects: 238

Group type: COMPARATOR
Intervention: No implementation intention
Number of subjects: 238
Study: 19666118

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) plus Pitavastatin (2mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pitavastatin (2mg/day) alone
Number of subjects: 20
Study: 18602688

Group type: EXPERIMENTAL
Intervention: Vitespen (HSPPC-96); administered intradermally once a week for 4 weeks, then every 2 weeks until vaccine depletion
Number of subjects: 728

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Vitespen (HSPPC-96); administered intradermally
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Vitespen (HSPPC-96)
Number of subjects: 728
Study: 16007029

Group type: EXPERIMENTAL
Intervention: Esmolol (n=22)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy (n=18)
Number of subjects: 40
Study: 12192554

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with doses of 150 Gy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with doses of 300 Gy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with target dose of 256 Gy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 224
Study: 10353922

Group type: EXPERIMENTAL
Intervention: Fortified human milk (FHM, n = 62)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Preterm formula (PF, n = 46)
Number of subjects: 108
Study: 8610612

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg once daily
Number of subjects: 54
Study: 2010374

Group type: EXPERIMENTAL
Intervention: Exercise at various intensities and durations (30 min at 65% VO2max, 60 min at 30% VO2max, 60 min at 75% VO2max, 120 min at 65% VO2max)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased exercise intensity in the highly fit group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 0
Study: 7028260

Group type: EXPERIMENTAL
Intervention: VP-16-213 alone (group 1)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: VP-16-213 combined with cyclophosphamide (group 2)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: VP-16-213 combined with doxorubicin (group 3)
Number of subjects: 118
Study: 31009768

Group type: EXPERIMENTAL
Intervention: 1 mm allograft bone particles (ABP) augmentation in groups A1 and A2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Full (100%) trajectory augmentation with 1 mm ABP in groups B1 and B2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mm ABP vs 2 mm ABP in groups C1 and C2
Number of subjects: 60
Study: 28272197

Group type: EXPERIMENTAL
Intervention: Programmed standing exercises and assisted standing for more than 2 hours a day, more than 5 days a week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy with a standing program for 20 minutes a day, 2 to 3 days a week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 12
Study: 26076989

Group type: COMPARATOR
Intervention: Chocolate consumption <1 per month (reference group)
Number of subjects: 18819

Group type: EXPERIMENTAL
Intervention: Chocolate consumption 1 to 3 per month
Number of subjects: 18819

Group type: EXPERIMENTAL
Intervention: Chocolate consumption 2 to 4 per week
Number of subjects: 18819

Group type: EXPERIMENTAL
Intervention: >5 per week
Number of subjects: 18819
Study: 23656493

Group type: EXPERIMENTAL
Intervention: Plasma TNF-α levels in RM patients during early pregnancy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Carriage of TNFA -863C and TNFA -1031T polymorphisms
Number of subjects: 47
Study: 20163941

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention (L)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Metformin (M)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 203
Study: 19268676

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 40

Group type: COMPARATOR
Intervention: No chewing gum (Control)
Number of subjects: 40
Study: 17711689

Group type: EXPERIMENTAL
Intervention: Stable angina pectoris (SAP) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Coronary artery spasm (CAS) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multi-vessel disease group (SAP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Single-vessel disease group (SAP)
Number of subjects: 90
Study: 15585768

Group type: EXPERIMENTAL
Intervention: Green tea extract supplement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Black tea
Number of subjects: 30

Group type: COMPARATOR
Intervention: Green tea
Number of subjects: 30
Study: 11723089

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 572

Group type: COMPARATOR
Intervention: Conventional therapy (diuretics and/or beta-blockers)
Number of subjects: 572
Study: 8995946

Group type: EXPERIMENTAL
Intervention: Citrucel, 1 tablespoon twice daily
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pectin, 1 tablespoon twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 13
Study: 8515979

Group type: EXPERIMENTAL
Intervention: Controlled-release ibuprofen 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular ibuprofen 200 mg (3 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Codeine 30 mg (3 doses)
Number of subjects: 0
Study: 3574383

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 30809700

Group type: EXPERIMENTAL
Intervention: BetterStim sacral neuromodulation system (treatment group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (stimulation delayed for 3 months)
Number of subjects: 84
Study: 30032506

Group type: EXPERIMENTAL
Intervention: P15 (15 mmHg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: P12 (12 mmHg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 26833235

Group type: EXPERIMENTAL
Intervention: Negative Pressure Closure (NPC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Mesh-Mediated Fascial Traction Closure (MMFC)
Number of subjects: 53
Study: 25136078

Group type: EXPERIMENTAL
Intervention: BM CD34(+) cell percentage
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: BM-derived endothelial colonies
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: BM CD11b(+) cells
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: BM CD34(+) percentage
Number of subjects: 280
Study: 22463388

Group type: EXPERIMENTAL
Intervention: Stress group (participants who participated in a speech test that increased anxiety and threatened self-esteem)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (participants not subjected to the stress manipulation)
Number of subjects: 0
Study: 19921102

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb-IIIa inhibitors with Drug-Eluting Stents (DES)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Glycoprotein IIb-IIIa inhibitors with Bare Metal Stents (BMS)
Number of subjects: 270
Study: 18570578

Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam (2-8 g/day)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Ceftazidime-amikacin-metronidazole (2-6 g/day, 15 mg/kg/day, 500 mg three times daily)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam
Number of subjects: 306

Group type: COMPARATOR
Intervention: Ceftazidime-amikacin-metronidazole
Number of subjects: 306
Study: 15845094

Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion (0.5 M, 5 mL/kg body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% NaCl infusion
Number of subjects: 20
Study: 12093324

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 150 mg/day)
Number of subjects: 0
Study: 10064170

Group type: COMPARATOR
Intervention: Oral isoprinosine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral isoprinosine plus intraventricular alpha-interferon
Number of subjects: 8
Study: 8756801

Group type: EXPERIMENTAL
Intervention: Salmeterol (Sm) 50 micrograms twice daily
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Salbutamol (Sb) 200 micrograms four times daily
Number of subjects: 367

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 367
Study: 1901200

Group type: EXPERIMENTAL
Intervention: Rifater (combined formulation)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Separate drugs
Number of subjects: 310
Study: 6812144

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5HTP) with carbidopa
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 7
Study: 31449261

Group type: EXPERIMENTAL
Intervention: Iterative selection and amplification of sequences starting with a randomized sequence pool; in vitro binding assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro and in vivo functional assays
Number of subjects: 0
Study: 28991149

Group type: EXPERIMENTAL
Intervention: Fluid Outpatient Rehabilitation Treatment (FORT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional treatment planning
Number of subjects: 52
Study: 27256458

Group type: EXPERIMENTAL
Intervention: Preheated skin disinfectant solution (36 °C)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Room-temperature skin disinfectant solution (20 °C)
Number of subjects: 220
Study: 25150038

Group type: EXPERIMENTAL
Intervention: Four sessions of motivational interviewing and stress management‐relaxation in addition to standard cardiac rehabilitation
Number of subjects: 135

Group type: COMPARATOR
Intervention: Cardiac rehabilitation alone
Number of subjects: 135
Study: 21908049

Group type: EXPERIMENTAL
Intervention: Modified version of the 'Mother‐Infant Transaction Program' (intervention group)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group (preterm infants)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Term infants (comparison group)
Number of subjects: 214
Study: 19169899

Group type: EXPERIMENTAL
Intervention: Home-based intervention program (HBIP)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 185
Study: 17239678

Group type: EXPERIMENTAL
Intervention: Early treatment with intracoronary injection of BM-SCs
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Early treatment with combined application of BM-SCs
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Late treatment with intracoronary delivery of BM-SCs
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Late treatment with combined administration of BM-SCs
Number of subjects: 360

Group type: COMPARATOR
Intervention: Standardized treatment of AMI (control for all groups)
Number of subjects: 360
Study: 15814220

Group type: EXPERIMENTAL
Intervention: RetCam 120
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indirect ophthalmoscope with eyelid speculum
Number of subjects: 15

Group type: COMPARATOR
Intervention: Indirect ophthalmoscope without eyelid speculum
Number of subjects: 15
Study: 12032655

Group type: EXPERIMENTAL
Intervention: Natural beta-carotene (25,000 IU/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Natural vitamin E (400 IU/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination beta-carotene and vitamin E
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10580202

Group type: EXPERIMENTAL
Intervention: Three doses at 2, 4, and 6 months
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Third dose in the Swedish arm
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Fourth dose in the US arm
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Higher diphtheria toxoid dose (25 Lf) in the Swedish arm
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Higher tetanus toxoid dose (7 Lf) in the Swedish arm
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Increasing the number of doses, prolonging intervals between doses, and increasing antigen amount
Number of subjects: 221
Study: 8532944

Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Quinapril 20 mg once daily
Number of subjects: 50
Study: 1840300

Group type: EXPERIMENTAL
Intervention: Light cured composite resin A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Light cured composite resin B
Number of subjects: 20
Study: 6357677

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.1 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29117618

Group type: EXPERIMENTAL
Intervention: Flaxseed oil omega-3 fatty acids (1,000 mg, twice a day for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27146857

Group type: EXPERIMENTAL
Intervention: Labile group received reminders designed to return memories to a labile state.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Stable group received reminders designed to leave memories in a stable state.
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Labile group
Number of subjects: 2
Study: 25399012

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500mg/d for 3 months)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 154
Study: 22290281

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 623

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 623
Study: 20099350

Group type: EXPERIMENTAL
Intervention: 1 mL/second injection rate of gadoxetic acid
Number of subjects: 126

Group type: COMPARATOR
Intervention: 2 mL/second injection rate of gadoxetic acid
Number of subjects: 126
Study: 18294024

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 to 10 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lamotrigine 50 to 200 mg/day
Number of subjects: 47
Study: 17213049

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (CBT) program; specific dosage and duration not mentioned.
Number of subjects: 48
Study: 14570627

Group type: EXPERIMENTAL
Intervention: Dopamine 2 microg kg(‐1x. min(‐1) from the induction of anesthesia to 1 h post‐CPB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mannitol 1 g/kg added to the CPB prime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mannitol plus dopamine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mannitol alone
Number of subjects: 100
Study: 10951308

Group type: EXPERIMENTAL
Intervention: Lumbar side‐posture spinal adjusting
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Side‐posture positioning
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 16
Study: 9007710

Group type: EXPERIMENTAL
Intervention: 6-month interferon alpha-2b therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 12-month interferon alpha-2b therapy
Number of subjects: 60
Study: 1889950

Group type: EXPERIMENTAL
Intervention: Naseptin antiseptic carrier cream
Number of subjects: 48

Group type: COMPARATOR
Intervention: Silver nitrate cautery
Number of subjects: 48
Study: 6362203

Group type: EXPERIMENTAL
Intervention: Reduced dose regimen (once-a-day application of fluocinonide combined with three-times-a-day application of its vehicle)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional dose regimen (four-times-a-day application of fluocinonide)
Number of subjects: 52
Study: 31962344

Group type: EXPERIMENTAL
Intervention: D1 agonist (specific doses not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D1 agonist (higher doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30730430

Group type: EXPERIMENTAL
Intervention: NH‐SiO2
Number of subjects: 40

Group type: COMPARATOR
Intervention: Homologous bone
Number of subjects: 40
Study: 28931586

Group type: EXPERIMENTAL
Intervention: Low added sugars (LAS) diet (5% AS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High added sugars (HAS) diet (25% AS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 33
Study: 27538847

Group type: EXPERIMENTAL
Intervention: Animated home-based exercise program using the Wii game console for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional home-based physical exercise program for 12 weeks
Number of subjects: 30
Study: 25124362

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 0.4 U/kg
Number of subjects: 20
Study: 23070990

Group type: EXPERIMENTAL
Intervention: Educational intervention (monthly Web-based conferences and articles on targeting care in RA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 50
Study: 18562432

Group type: EXPERIMENTAL
Intervention: Antidepressants (fluoxetine, duloxetine, or Hypericum perforatum)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 34
Study: 17550714

Group type: EXPERIMENTAL
Intervention: Intrarater reliability assessment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interrater reliability assessment for anterior or posterior angulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Interrater reliability assessment for varus or valgus angulation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Measurement change assessment
Number of subjects: 30
Study: 15368877

Group type: EXPERIMENTAL
Intervention: Combination of anorganic bovine-derived hydroxyapatite matrix (ABM) and cell binding peptide (P-15)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open flap debridement (DEBR)
Number of subjects: 10
Study: 11445595

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (3 times/week for 24 weeks, 2 sets of 8-15 repetitions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 9875874

Group type: EXPERIMENTAL
Intervention: Alendronate sodium (5 mg/d for 2 years, then 10 mg/d for the remainder of the trial)
Number of subjects: 4432

Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Number of subjects: 4432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4432
Study: 8040954

Group type: EXPERIMENTAL
Intervention: Early endarterectomy (CE) performed within 30 days after stroke (n=42)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed endarterectomy (CE) performed beyond 30 days after stroke (n=58)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Early endarterectomy (CE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed endarterectomy (CE)
Number of subjects: 100
Study: 2647398

Group type: EXPERIMENTAL
Intervention: CDP-Choline, 500 mg twice a day orally for 2 to 8 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30537305

Group type: EXPERIMENTAL
Intervention: High-protein meal (60 g protein)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-protein meal (5 g protein)
Number of subjects: 11
Study: 28435034

Group type: EXPERIMENTAL
Intervention: Cytoreductive radical prostatectomy (cRP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 46
Study: 25795462

Group type: EXPERIMENTAL
Intervention: Short-term fasting (36 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (overnight fast)
Number of subjects: 9
Study: 22797831

Group type: EXPERIMENTAL
Intervention: Pharmacist discharge counseling
Number of subjects: 127

Group type: COMPARATOR
Intervention: Usual patient care
Number of subjects: 127
Study: 20102350

Group type: EXPERIMENTAL
Intervention: Haemorheopheresis (8 sessions within 10 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Haemorheopheresis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (25 eyes)
Number of subjects: 16
Study: 19766459

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 873

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 873
Study: 17088142

Group type: EXPERIMENTAL
Intervention: Amphotericin B nasal lavages (25 mL at 100 microg/mL, twice daily for 3 months)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 15629023

Group type: EXPERIMENTAL
Intervention: Laser photo-coagulation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study: 11474324

Group type: EXPERIMENTAL
Intervention: Exercise in the fed state (2 hours after a standardized breakfast)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Exercise in the fasted state
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exercise in the fed state
Number of subjects: 10